Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 44.25 and traded as low as GBX 42.50. Faron Pharmaceuticals Oy shares last traded at GBX 43.95, with a volume of 17,943 shares.
Faron Pharmaceuticals Oy Price Performance
The stock’s 50-day moving average is GBX 44.25 and its 200-day moving average is GBX 97.66. The firm has a market cap of £87.69 million, a P/E ratio of -1.99 and a beta of 1.11. The company has a quick ratio of 1.09, a current ratio of 0.84 and a debt-to-equity ratio of -133.35.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
